U.S. markets open in 3 hours 38 minutes

LeMaitre Vascular, Inc. (LMAT)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
46.82-3.96 (-7.80%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
MACD

MACD

Previous Close50.78
Open50.41
Bid0.00 x 800
Ask0.00 x 3000
Day's Range46.30 - 50.42
52 Week Range18.76 - 54.96
Volume204,009
Avg. Volume127,400
Market Cap952.412M
Beta (5Y Monthly)1.34
PE Ratio (TTM)45.02
EPS (TTM)1.04
Earnings DateFeb 25, 2021
Forward Dividend & Yield0.44 (0.87%)
Ex-Dividend DateMar 08, 2021
1y Target Est54.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
-11% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • LeMaitre Vascular inc (LMAT) Q4 2020 Earnings Call Transcript
    Motley Fool

    LeMaitre Vascular inc (LMAT) Q4 2020 Earnings Call Transcript

    Image source: The Motley Fool. LeMaitre Vascular inc (NASDAQ: LMAT)Q4 2020 Earnings CallFeb 25, 2021, 5:00 p.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorWelcome to the LeMaitre Vascular Q4 2020 Financial Results Conference Call.

  • Benzinga

    Recap: LeMaitre Vascular Q4 Earnings

    Shares of LeMaitre Vascular (NASDAQ:LMAT) were flat in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share increased 47.83% over the past year to $0.34, which beat the estimate of $0.29. Revenue of $37,548,000 up by 24.45% from the same period last year, which beat the estimate of $35,580,000. Looking Ahead LeMaitre Vascular hasn't issued any earnings guidance for the time being. LeMaitre Vascular hasn't issued any revenue guidance for the time being. Conference Call Details Date: Feb 25, 2021 View more earnings on LMAT Time: 05:00 PM ET Webcast URL: https://edge.media-server.com/mmc/p/cmk74ikf Recent Stock Performance 52-week high: $50.53 52-week low: $18.76 Price action over last quarter: Up 43.01% Company Overview LeMaitre Vascular Inc manufactures and distributes medical devices for the treatment of peripheral vascular disease. Its products are primarily used during open vascular surgery and address several anatomical areas, such as the carotid, lower extremities, upper extremities, and aorta. The firm's lower extremities product line contributes the largest proportion of revenue, followed by the carotid product line. LeMaitre's surgical devices include angioscopes, balloon catheters, carotid shunts, phlebectomy devices, vascular grafts, vascular patches, and vessel closure systems. LeMaitre generates the majority of its revenue in the United States. Sales in Germany also contribute a significant proportion of total revenue. See more from BenzingaClick here for options trades from BenzingaEarnings Preview for LeMaitre VascularBenzinga's Top Ratings Upgrades, Downgrades For February 12, 2021© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.